Biography and Research Information
OverviewAI-generated summary
Fumou Sun investigates multiple myeloma, focusing on cellular mechanisms and potential therapeutic strategies. His research explores the role of specific genes and proteins, such as FOXM1 and NEK2, in regulating cancer cell metabolism, energy production, and immune suppression within the tumor microenvironment. Sun has also examined the efficacy of novel immunotherapies, including bispecific CAR-T cells targeting BCMA and CD24, and fusion antibodies that enhance immunotherapy effects by blocking PD-1. Additionally, his work has investigated the impact of certain compounds, like Baicalin, on autophagy and graft-versus-host disease, as well as the mechanisms by which CST6 suppresses osteolytic bone disease in multiple myeloma.
Sun's scholarship metrics include an h-index of 18, with 67 total publications and 848 total citations. He has a significant collaborative network at the University of Arkansas for Medical Sciences, with numerous shared publications with John D. Shaughnessy, Guido Tricot, David E. Mery, and Dongzheng Gai.
Metrics
- h-index: 18
- Publications: 67
- Citations: 860
Selected Publications
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024)
-
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)
-
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing (2024)
-
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)
-
A 5-Stage System for ASCT Multiple Myeloma (2023)
-
Prognostic Value of Ferritin in ASCT MM Patients: Integration with GEP Models and ISS Series Systems (2023)
-
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)
-
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)
-
P-066 BCMA-CAR-T cells with synthetic circuits of CST6 lyse tumor cells and suppress osteolytic lesions in multiple myeloma (2023)
Collaboration Network
Top Collaborators
- FOXM1 regulates glycolysis and energy production in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 25 shared publications
- FOXM1 regulates glycolysis and energy production in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- WDR26 and MTF2 are therapeutic targets in multiple myeloma
Showing 5 of 23 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 21 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 19 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 17 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 17 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 17 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 16 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 16 shared publications
- Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma
- Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
- Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
- Supplementary Figure from Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
- Supplementary Figure from Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma
Showing 5 of 14 shared publications
- FOXM1 regulates glycolysis and energy production in multiple myeloma
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 14 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 14 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 13 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 12 shared publications
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 12 shared publications
Similar Researchers
Based on overlapping research topics